The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection

Antiviral Research

Volumn 38, Issue 3, 1998, Pages 153-179

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Delavirdine; HIV; Nevirapine; NNRTIs (non nucleoside reverse transcriptase inhibitors); Reverse transcriptase; Triple drug combinations

Indexed keywords

ALKOXY(ARYLTHIO)URACIL; BENZOTHIADIAZINE DERIVATIVE; BENZYLOXYMETHYLPYRIDINONE; CANALONIDE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; IMIDAZOPYRIDAZINE; INDOLYLDIPYRIDODIAZEPINONE; LOVIRIDE; MEN 10979; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; PYRITHYLDIONE; PYRROLOBENZODIAZEPINONE; QUINAZOLINONE DERIVATIVE; QUINOXALINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE; THIAZOLOBENZIMIDAZOLE; THIAZOLOISOINDOLINONE; THIOCARBOXANILIDE; TIVIRAPINE; TROVIRDINE; U 31355; UNCLASSIFIED DRUG; ZIDOVUDINE;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 0032437454     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00025-4     Document Type: Article

References (146)

1. Ahrgren C., Backro K., Bell F.W., Cantrell A.S., Clemens M., Colacino J.M., Deeter J.B., Engelhardt J.A., Högberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., Kasher J.S., Kinnick M.D., Lind P., Lopez C., Morin J.M. Jr., Muesing M.A., Noreen R., Öberg B., Paget C.J., Palkowitz J.A., Parrish C.A., Pranc P., Rippy M.K., Rydergard C., Sahlberg C., Swanson S., Ternansky R.J., Unge T., Vasileff R.T., Vrang L., West S.J., Zhang H., Zhou X.-X. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;1329-1335.
2. Althaus I.W., Chou K.-C., Lemay R.J., Franks K.M., Deibel M.R., Kezdy F.J., Resnick L., Busso M.E., So A.G., Downey K.M., Romero D.L., Thomas R.C., Aristoff P.A., Tarpley W.G., Reusser F. The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase. Biochem. Pharmacol. 51:1996;743-750.
3. Antonucci T., Warmus J.S., Hodges J.C., Nickell D.G. Characterization of the antiviral activity of highly substituted pyrroles: a novel class of non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 6:1995;98-108.
4. Artico M., Massa S., Mai A., Marongiu M.E., Piras G., Tramontano E., La Colla P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): a new class of specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 4:1993;361-368.
5. Baba M., Tanaka H., De Clercq E., Pauwels R., Balzarini J., Schols D., Nakashima H., Perno C.-F., Walker R.T., Miyasaka T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165:1989;1375-1381.
6. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Nakashima H., Mori S., Shigeta S., Walker R.T., Miyasaka T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 88:1991;2356-2360.
7. Baba M., De Clercq E., Tanaka H., Ubasawa M., Takashima H., Sekiya K., Nitta I., Umezu K., Walker R.T., Mori S., Ito M., Shigeta S., Miyasaka T. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 39:1991;805-810.
8. Baba M.M., Shigeta S., Yuasa S., Takashima H., Sekiya K., Ubasawa M., Tanaka H., Miyasaka T., Walker R.T., De Clercq E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:1994;688-692.
9. Balzarini J., De Clercq E. The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs. Antiviral Chem. Chemother. 8:1997;197-204.
10. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Schols D., Perno C.-F., Vandamme A.-M., Camarasa M.-J., De Clercq E. 2′,5′-Bis-O-(tert.-butyldimethylsilyl)-3′-spiro- 5′′(4′′amino-1′′,2′′oxathiole- 2′′,2′′-dioxide)pyrimidine (TSAO) nucleoside analogues: novel highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA. 89:1992;4392-4396.
11. Balzarini J., Perez-Perez M.-J., San-Felix A., Velazquez S., Camarasa M.-J., De Clercq E. [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro- 5′′-[4′′-amino-1′′,2′′- oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 36:1992;1073-1080.
12. Balzarini J., Pérez-Pérez M.-J., San-Félix A., Camarasa M.-J., Barr P.J., De Clercq E. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5′′-(4′′-amino-1′′, 2′′-oxathiole-2′′,2′′-di-oxide)thymine (TSAO-T). J. Biol. Chem. 267:1992;11831-11838.
13. Balzarini J., Karlsson A., Pérez-Pérez M.-J., Camarasa M.-J., De Clercq E. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology. 196:1993;576-585.
14. Balzarini J., Karlsson A., Meichsner C., Paessens A., Riess G., De Clercq E., Kleim J.-P. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:1994;7986-7992.
15. Balzarini J., Brouwer W.G., Felauer E.E., De Clercq E., Karlsson A. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 27:1995;219-236.
16. Balzarini J., Baba M., De Clercq E. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains. Antimicrob. Agents Chemother. 39:1995;998-1002.
17. Balzarini J., Pérez-Pérez M.-J., Vélazquez S., San-Félix A., Camarasa M.-J., De Clercq E., Karlsson A. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc. Natl. Acad. Sci. USA. 92:1995;5470-5474.
18. Balzarini J., Pelemans H., Pérez-Pérez M.-J., San-Félix A., Camarasa M.-J., Karlsson A. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 49:1996;882-890.
19. Balzarini J., Pelemans H., Aquaro S., Perno C.-F., Witvrouw M., Schols D., De Clercq E., Karlsson A. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 50:1996;394-401.
20. Balzarini J., Pelemans H., Karlsson A., De Clercq E., Kleim J.-P. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA. 93:1996;13152-13157.
21. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., Kleim J.-P. Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine. J. Infect. Dis. 176:1997;1392-1397.
22. Balzarini J., Pelemans H., Esnouf R., De Clercq E. A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781. AIDS Res. Hum. Retroviruses. 14:1998;255-260.
23. Balzarini J., Pelemans H., Riess G., Roesner M., Winkler I., De Clercq E., Kleim J.-P. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline- 2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine). Biochem. Pharmacol. 55:1998;617-625.
24. Barth B., Dierich M., Heinisch G., Jenny V., Matuszczak B., Mereiter K., Planer R., Schöpf I., Stoiber H., Traugott T., von Aufschnaiter P. Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation. Antiviral Chem. Chemother. 7:1996;300-312.
25. Bellarosa D., Antonelli G., Bambacioni F., Giannotti D., Viti G., Nannicini R., Giachetti A., Dianzani F., Witvrouw M., Pauwels R., Desmyter J., De Clercq E. New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 30:1996;109-124.
26. Boyer P.L., Ding J., Arnold E., Hughes S.H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:1994;1909-1914.
27. Boyer P.L., Gao H.-Q., Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:1998;447-452.
28. Brennan T.M., Taylor D.L., Bridges C.G., Leyda J.P., Tyms A.S. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral Res. 26:1995;173-187.
29. Buckheit R.W. Jr., Hollingshead M.G., Germany-Decker J., White E.L., McMahon J.B., Allen L.B., Ross L.J., Decker W.D., Westbrook L., Shannon W.M., Weislow O., Bader J.P., Boyd M.R. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 21:1993;247-265.
30. Buckheit R.W. Jr., Fliakas-Boltz V., Decker W.D., Roberson J.L., Pyle C.A., White E.L., Bowdon B.J., McMahon J.B., Boyd M.R., Bader J.P., Nickell D.G., Barth H., Antonucci T.K. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors. Antiviral Res. 25:1994;43-56.
31. Buckheit R.W. Jr., White E.L., Germany-Decker J., Allen L.B., Ross L.J., Shannon W.M., Janssen P.A.J., Chirigos M.A. Cell-based and biochemical analysis of the anti-HIV activity of combinations of 3′-azido-3′-deoxythymidine and analogues of TIBO. Antiviral Chem. Chemother. 5:1994;35-42.
32. Buckheit R.W. Jr., Fliakas-Boltz V., Yeagy-Bargo S., Weislow O., Mayers D.L., Boyer P.L., Hughes S.H., Pan B.-C., Chu S.-H., Bader J.P. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology. 210:1995;186-193.
33. Buckheit R.W. Jr., Snow M.J., Fliakas-Boltz V., Kinjerski T.L., Russell J.D., Pallansch L.A., Brouwer W.G., Yang S.S. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents Chemother. 41:1997;831-837.
34. Byrnes V.W., Emini E.A., Schleif W.A., Condra J.H., Schneider C.L., Long W.J., Wolfgang J.A., Graham D.J., Gotlib L., Schlabach A.J., Wolanski B.S., Blahy O.M., Quintero J.C., Rhodes A., Roth E., Titus D.L., Sardana V.V. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 38:1994;1404-1407.
35. CAESAR Coordinating Committee Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 349:1997;1413-1421.
36. Campiani G., Nacci V., Fiorini I., De Filippis M.P., Garofalo A., Greco G., Novellino E., Altamura S., Di Renzo L. Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity. J. Med. Chem. 39:1996;2672-2680.
37. Cao Y., Qin L., Zhang L., Safrit J., Ho D.D. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. New Engl. J. Med. 332:1995;201-208.
38. Carr A., Vella S., de Jong M.D., Sorice F., Imrie A., Boucher C.A., Cooper D.A. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. AIDS. 10:1996;635-641.
39. Chimirri A., Grasso S., Molica C., Monforte A.-M., Monforte P., Zappalà M., Bruno G., Nicolò F., Witvrouw M., Jonckheere H., Balzarini J., De Clercq E. Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor. Antiviral Chem. Chemother. 8:1997;363-370.
40. Chong K.-T., Pagano P.J., Hinshaw R.R. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob. Agents Chemother. 38:1994;288-293.
41. Craib K.J.P., Strathdee S.A., Hogg R.S., Leung B., Montaner J.S.G., O'Shaughnessy M.V., Schechter M.T. Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection. J. Infect. Dis. 176:1997;798-800.
42. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, D'Aquila R.T., Hughes M.D., Johnson M.D., Johnson V.A., Fischl M.S., Sommadossi J.-P., Liou S.-H., Timpone J., Myers M., Myers M., Basgoz N., Niu M., Hirsch M.S. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124:1996;1019-1030.
43. Davey R.T. Jr., Dewar R.L., Reed G.F., Vasudevachari M.B., Polis M.A., Kovacs J.A., Falloon J., Walker R.E., Masur H., Haneiwich S.E., O'Neill D.G., Decker M.R., Metcalf J.A., Deloria M.A., Laskin O.L., Salzman N., Lane H.C. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. Proc. Natl. Acad. Sci. USA. 90:1993;5608-5612.
44. Davey R.T. Jr., Chaitt D.G., Reed G.F., Freimuth W.W., Herpin B.R., Metcalf J.A., Eastman P.S., Falloon J., Kovacs J.A., Polis M.A., Walker R.E., Masur H., Boyle J., Coleman S., Cox S.R., Wathen L., Daenzer C.L., Lane H.C. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1996;1657-1664.
45. Debyser Z., Pauwels R., Andries K., Desmyter J., Kukla M., Janssen P.A.J., De Clercq E. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Natl. Acad. Sci. USA. 88:1991;1451-1455.
46. Debyser Z., Pauwels R., Baba M., Desmyter J., De Clercq E. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase. Mol. Pharmacol. 41:1992;963-968.
47. De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:1995;200-239.
48. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:1996;125-157.
49. De Clercq E. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev. Med. Virol. 6:1996;97-117.
50. De Clercq E. In search of a selective antiviral chemotherapy. Clin. Microbiol. Rev. 10:1997;674-693.
51. De Jong M.D., Vella S., Carr A., Boucher C.A.B., Imrie A., French M., Hoy J., Sorice S., Pauluzzi S., Chiodo F., Weverling G.J., van der Ende M.E., Frissen Ph.J., Weigel H.M., Kauffmann R.H., Lange J.M.A., Yoon R., Moroni M., Hoenderdos E., Leitz G., Cooper D.A., Hall D., Reiss P. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J. Infect. Dis. 175:1997;966-970.
52. De Lucca G.V., Otto M.J. Synthesis and anti-HIV activity of pyrrolo-[1,2-d]-(1,4)-benzodiazepin-6-ones. Bioorg. Med. Chem. Lett. 2:1992;1639-1644.
53. De Wit S., Hermans P., Sommereijns B., O'Doherty E., Westenborghs R., Van De Velde V., Cauwenbergh G.F.M.J., Clumeck N. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob. Agents Chemother. 36:1992;2661-2663.
54. Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr., Jesen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P.A.J., Smith R.H. Jr., Kroeger Koepke M., Michejda C.J., Hughes S.H., Arnold E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure. 3:1995;365-379.
55. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., Arnold E. Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Struct. Biol. 2:1995;407-415.
56. Di Santo R., Costi R., Artico M., Massa S., Marongiu M.E., Loi A.G., De Montis A., La Colla P. 1,2,5-Benzothiadiazepine and pyrrolo[2,1-d][1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity. Antiviral Chem. Chemother. 9:1998;127-137.
57. Dollé V., Nguyen C.H., Aubertin A.M., Kirn A., Andreola M.L., Jamieson G., Tarrago-Litvak L., Bisagni E. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 38:1995;4679-4686.
58. Dueweke T.J., Kézdy F.J., Waszak G.A., Deibel M.R. Jr., Tarpley W.G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 267:1992;27-30.
59. Dueweke T.J., Poppe S.M., Romero D.L., Swaney S.M., So A.G., Downey K.M., Althaus I.W., Reusser F., Busso M., Resnick L., Mayers D.L., Lane J., Aristoff P.A., Thomas R.C., Tarpley W.G. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1993;1127-1131.
60. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S.Y., Stevenson M., Tarpley W.G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA. 90:1993;4713-4717.
61. Esnouf R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graphics. 15:1997;132-134.
62. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Struct. Biol. 2:1995;303-308.
63. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. USA. 94:1997;3984-3989.
64. Esnouf R.M., Stuart D.I., De Clercq E., Schwartz E., Balzarini J. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives. Biochem. Biophys. Res. Commun. 234:1997;458-464.
65. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 279:1997;1295-1300.
66. Goldman M.E., Nunberg J.H., O'Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., Gaul S.L., Saari W.S., Wai J.S., Hoffman J.M., Anderson P.S., Hupe D.J., Emini E.A., Stern A.M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA. 88:1991;6863-6867.
67. Goldman M.E., O'Brien J.A., Ruffing T.L., Nunberg J.H., Schleif W.A., Quintero J.C., Siegl P.K.S., Hoffman J.M., Smith A.M., Emini E.A. L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob. Agents Chemother. 36:1992;1019-1023.
68. Grob P.M., Cao Y., Muchmore E., Ho D.D., Norris S., Pav J.W., Shih C.-K., Adams J. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat. Med. 3:1997;665-670.
69. Havlir D.V., Richman D.D. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann. Intern. Med. 124:1996;984-994.
70. Havlir D., Cheeseman S.H., McLaughlin M., Murphy R., Erice A., Spector S.A., Greenough T.C., Sullivan J.L., Hall D., Myers M., Lamson M., Richman D.D. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171:1995;537-545.
71. 3: AIDS clinical trials group protocol 208. J. Infect. Dis. 172:1995;1379-1383.
72. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 373:1995;123-126.
73. Ijichi K., Fujiwara M., Hanasaki Y., Watanabe H., Katsuura K., Takayama H., Shirakawa S., Sakai S.-I., Shigeta S., Konno K., Yokota T., Baba M. Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives. Antimicrob. Agents Chemother. 39:1995;2337-2340.
74. Ijichi K., Fujiwara M., Nagano H., Matsumoto Y., Hanasaki Y., Ide T., Katsuura K., Takayama H., Shirakawa S., Aimi N., Shigeta S., Konno K., Matsushima M., Yokota T., Baba M. Anti-HIV-1 activity of thiadiazole derivatives: a structure-activity relationship, reverse transcriptase inhibition, and lipophilicity. Antiviral Res. 31:1996;87-94.
75. Ito M., Baba M., Shigeta S., De Clercq E., Walker R.T., Tanaka H., Miyasaka T. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon. Antiviral Res. 15:1991;323-330.
76. 138→Lys on the p51 subunit. J. Biol. Chem. 269:1994;25255-25258.
77. Jourdan F., Renault J., Fossey C., Bureau R., Ladurée D., Robba M., Aubertin A.M., Kirn A. Design, synthesis and antiviral activity of new pyridinone derivatives. Antiviral Chem. Chemother. 8:1997;161-172.
78. Kashman Y., Gustafson K.R., Fuller R.W., Cardellina II J.H., McMahon J.B., Currens M.J., Buckheit R.W. Jr., Hughes S.H., Cragg G.M., Boyd M.R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J. Med. Chem. 35:1992;2735-2743.
79. Kelly T.A., McNeil D.W., Rose J.M., David E., Shih C.-K., Grob P.M. Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones. J. Med. Chem. 40:1997;2430-2433.
80. Kim D.-K., Gam J., Kim Y.-W., Lim J., Kim H.-T., Kim K.H. Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils. J. Med. Chem. 40:1997;2363-2373.
81. Kleim J.-P., Bender R., Billhardt U.-M., Meichsner C., Riess G., Rösner M., Winkler I., Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1993;1659-1664.
82. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701.
83. Kleim J.-P., Bender R., Kirsch R., Meichsner C., Paessens A., Rösner M., Rübsamen-Waigmann H., Kaiser R., Wichers M., Schneweis K.E., Winkler I., Riess G. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:1995;2253-2257.
84. Kleim J.-P., Rösner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., Arnold E., Riess G. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA. 93:1996;34-38.
85. Kleim J.-P., Winkler I., Rösner M., Kirsch R., Rübsamen-Waigmann H., Paessens A., Riess G. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitory HBY 097. Virology. 231:1997;112-118.
86. Koup R.A., Merluzzi V.J., Hargrave K.D., Adams J., Grozinger K., Eckner R.J., Sullivan J.L. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J. Infect. Dis. 163:1991;966-970.
87. Kroeger Smith M.B., Rouzer C.A., Taneyhill L.A., Smith N.A., Hughes S.H., Boyer P.L., Janssen P.A.J., Moereels H., Koymans L., Arnold E., Ding J., Das K., Zhang W., Michejda C.J., Smith R.H. Jr. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4:1995;2203-2222.
88. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36:1992;2664-2669.
89. Livermore D.G.H., Bethell R.C., Cammack N., Hancock A.P., Hann M.M., Green D.V.S., Lamont R.B., Noble S.A., Orr D.C., Payne J.J., Ramsay M.V.J., Shingler A.H., Smith C., Storer R., Williamson C., Willson T. Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines. J. Med. Chem. 36:1993;3784-3794.
90. Luzuriaga K., Bryson Y., Krogstad P., Robinson J., Stechenberg B., Lamson M., Cort S., Sullivan J.L. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. New Engl. J. Med. 336:1997;1343-1349.
91. Maass G., Immendoerfer U., Koenig B., Leser U., Mueller B., Goody R., Pfaff E. Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:1993;2612-2617.
92. Marschner I.C., Collier A.C., Coombs R.W., D'Aquila R.T., DeGruttola V., Fischl M.A., Hammer S.M., Hughes M.D., Johnson V.A., Katzenstein D.A., Richman D.D., Smeaton L.M., Spector S.A., Saag M.S. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:1998;40-47.
93. Massa S., Mai A., Artico M., Sbardella G., Tramontano E., Loi A.G., Scano P., La Colla P. Synthesis and antiviral activity of new 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), specific inhibitors of human immunodeficiency virus type 1. Antiviral Chem. Chemother. 6:1995;1-8.
94. Mayers, D., Riddler, S., Bach, M., Stein, D.F., Havlir, M.D., Kahn, J., Ruiz, N., Labriola, D.F. and the DMP 266 Clinical Development Team, 1997. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 30 September 1997, abstract I-175.
95. Mellors J.W., Dutschman G.E., Im G.-J., Tramontano E., Winkler S.R., Cheng Y.-C. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:1992;446-451.
96. Mellors J.W., Im G.-J., Tramontano E., Winkler S.R., Medina D.J., Dutschman G.E., Bazmi H.Z., Piras G., Gonzalez C.J., Cheng Y.-C. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)-imidazo[4,5,1-jk][1, 4]benzodiazepin-2(1H)-thione (TIBO R82150). Mol. Pharmacol. 43:1993;11-16.
97. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
98. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.-K., Eckner K., Hattox S., Adams J., Rosenthal A.S., Faanes R., Eckner R.J., Koup R.A., Sullivan J.L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413.
99. Mertens A., Zilch H., Konig B., Schafer W., Poll T., Kampe W., Seidel H., Leser U., Leinert H. Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9H)-ones and related compounds with anti-HIV-1 activity. J. Med. Chem. 36:1993;2526-2535.
100. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., De Clercq E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:1989;2507-2509.
101. Moxham C.P., Borroto-Esoda K., Noel D., Furman P.A., Szczech G.M., Barry D.W. Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers. Abstracts of the Tenth International Conference on Antiviral Research, Atlanta, GA, 6-11 April 1997. Antiviral Res. 34(2):1997;A44.
102. Nunberg J.H., Schleif W.A., Boots E.J., O'Brien J.A., Quintero J.C., Hoffman J.M., Emini E.A., Goldman M.E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:1991;4887-4892.
103. Veterans Affairs Cooperative Study Group on AIDS, O'Brien W.A., Hartigan P.M., Martin D., Esinhart J., Hill A., Benoit S., Rubin M., Simberhoff M.S., Hamilton J.D. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New Engl. J. Med. 334:1996;426-431.
104. Okamoto M., Makino M., Yamada K., Nakade K., Yuasa S., Baba M. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antiviral Res. 31:1996;69-77.
105. Pagano P.J., Chong K.-T. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α J. Infect. Dis. 171:1995;61-71.
106. Pantaleo G., Menzo S., Vaccarezza M., Graziosi C., Cohen O.J., Demarest J.F., Montefiori D., Orenstein J.M., Fox C., Schrager L.K., Margolick J.B., Buchbinder S., Giorgi J.V., Fauci A.S. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New Engl. J. Med. 332:1995;209-216.
107. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J., Schellekens K., Janssen M.A.C., De Clercq E., Janssen P.A.J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 343:1990;470-474.
108. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., De Vreese K., Woestenborghs R., Vandamme A.-M., Janssen C.G.M., Anné J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., Janssen P.A.J. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA. 90:1993;1711-1715.
109. Pauwels R., Andries K., Debyser Z., Kukla M.-J., Schols D., Breslin H.J., Woestenborghs R., Desmyter J., Janssen M.A.C., De Clercq E., Janssen P.A.J. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 38:1994;2863-2870.
110. Pelemans H., Esnouf R., Dunkler A., Parniak M.A., Vandamme A.-M., Karlsson A., De Clercq E., Kleim J.-P., Balzarini J. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J. Virol. 71:1997;8195-8203.
111. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
112. Pialoux G., Youle M., Dupont B., Gazzard B., Cauwenbergh G.F.M.J., Stoffels P.A.M., Davies S., De Saint Martin J., Janssen P.A.J. Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex. Lancet. 338:1991;140-143.
113. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., Stammers D. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Struct. Biol. 2:1995;293-302.
114. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure. 3:1995;915-926.
115. Richman D., Shih C.-K., Lowy I., Rose J., Prodanovich P., Goff S., Griffin J. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA. 88:1991;11241-11245.
116. Richman D., Rosenthal A.S., Skoog M., Eckner R.J., Chou T.-C., Sabo J.P., Merluzzi V.J. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. 35:1991;305-308.
117. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., Shih C.-K., Myers M., Griffin J. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
118. Romero D.L., Busso M., Tan C.-K., Reusser F., Palmer J.R., Poppe S.M., Aristoff P.A., Downey K.M., So A.G., Resnick L., Tarpley W.G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA. 88:1991;8806-8810.
119. Romero D.L., Morge R.A., Genin M.J., Biles C., Busso M., Resnick L., Althaus I.W., Reusser F., Thomas R.C., Tarpley W.G. Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino] pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate. J. Med. Chem. 36:1993;1505-1508.
120. Rübsamen-Waigmann H., Huguenel E., Paessens A., Kleim J.-P., Wainberg M.A., Shah A. Second-generation non-nucleoside reverse transcriptase inhibitor HBY 097 and HIV-1 viral load. Lancet. 349:1997;1517.
121. L-697,661 Working Group, Saag M.S., Emini E.A., Laskin O.L., Douglas J., Lapidus W.I., Schleif W.A., Whitley R.J., Hildebrand C., Byrnes V.W., Kappes J.C., Anderson K.W., Massari F.E., Shaw G.M. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. New Engl. J. Med. 329:1993;1065-1072.
122. Saag M.S., Holodniy M., Kuritzkes D.R., O'Brien W.A., Coombs R., Poscher M.E., Jacobsen D.M., Shaw G.M., Richman D.D., Volberding P.A. HIV viral load markers in clinical practice. Nat. Med. 2:1996;625-629.
123. Sahai J. Risks and synergies from drug interactions. AIDS. 10(Suppl. 1):1996;S21-S25.
124. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News. 5:1997;129-142.
125. ACTG 184 Protocol Team, Schooley R.T., Campbell T.B., Kuritzkes D.R., Blaschke T., Stein D.S., Rosandich M.E., Phair J., Pottage J.C., Messari F., Collier A., Kahn J. Phase 1 study of combination therapy with L-697,661 and zidovudine. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12:1996;363-370.
126. Seki M., Sadakata Y., Yuasa S., Baba M. Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem. Chemother. 6:1995;73-79.
127. Silvestri R., Artico M., Bruno B., Massa S., Novellino E., Greco G., Marongiu M.E., Pani A., De Montis A., La Colla P. Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126. Antiviral Chem. Chemother. 9:1998;139-148.
128. Skowron, G., Leoung, G., Dusek, A., Anderson, R., Grosso, R., Jacobs, M., Lamson, M., Kerr, B., Beebe, S., 1998. dNN study: stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): preliminary safety, activity, and pharmacokinetic (PK) interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1-5 February 1998, abstract 350.
129. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;988-993.
130. Staszewski S., Massari F.E., Kober A., Gohler R., Durr S., Anderson K.W., Schneider C.L., Waterbury J.A., Bakshi K.K., Taylor V.I., Hildebrand C.S., Kreisl C., Hoffstedt B., Schleif W.A., von Briesen H., Rübsamen-Waigmann H., Calandra G.B., Ryan J.L., Stille W., Emini E.A., Byrnes V.W. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high level resistance to L-697,661, a non-nucleoside reverse transcriptase inhibitor. J. Infect. Dis. 171:1995;159-165.
131. Members of the Loviride Collaborative Study Group, Staszewski S., Miller V., Kober A., Colebunders R., Vandercam B., Delescluse J., Clumeck N., Van Wanzeele F., De Brabander M., De Creé J., Moeremans M., Andries K., Boucher C., Stoffels P., Janssen P.A.J. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1:1996;42-50.
132. Staszewski S., Miller V., Rehmet S., Stark T., De Creé J., De Brabander M., Peeters M., Andries K., Moeremans M., De Raeymaeker M., Pearce G., Van Den Broeck R., Verbiest W., Stoffels P. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS. 10:1996;F1-F7.
133. Tantillo C., Ding J., Jacobo-Molina A., Nanni R.G., Boyer P.L., Hughes S.H., Pauwels R., Andries K., Janssen P.A.J., Arnold E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:1994;369-387.
134. Terrett N.K., Bojanic D., Merson J.R., Stephenson P.T. Imidazo[2′,3′:6,5]dipyrido[3,2-b:2′,3′-e]-1,4- diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine. Bioorg. Med. Chem. Lett. 2:1992;1745-1750.
135. Tucker T.J., Lyle T.A., Wiscount C.M., Britcher S.F., Young S.D., Sanders W.M., Lumma W.C., Goldman M.E., O'Brien J.A., Ball R.G., Homnick C.F., Schleif W.A., Emini E.A., Huff J.R., Anderson P.S. Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 37:1994;2437-2444.
136. Vasudevachari M.B., Battista C., Lane H.C., Psallidopoulos M.C., Zhao B., Cook J., Palmer J.R., Romero D.L., Tarpley W.G., Salzman N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology. 190:1992;269-277.
137. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M.A., Gu Z., Song Q., Manne J., Islam S., Castriota G., Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 271:1996;1282-1285.
138. Wei X., Ghosh S.K., Taylor M.E., Johnson V.A., Emini E.A., Deutsch P., Lifson J.D., Bonhoeffer S., Nowak M.A., Hahn B.H., Saag M.S., Shaw G.M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 373:1995;117-122.
139. Williams T.M., Ciccarone T.M., MacTough S.C., Rooney C.S., Balani S.K., Condra J.H., Emini E.A., Goldman M.E., Greenlee W.J., Kauffman L.R., O'Brien J.A., Sardana V.V., Schleif W.A., Theoharides A.D., Anderson P.S. 5-Chloro-3-(phenylsulfonyl)indole-2-caboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. 36:1993;1291-1294.
140. Winslow D.L., Garber S., Reid C., Scarnati H., Baker D., Rayner M.M., Anton E.D. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS. 10:1996;1205-1209.
141. Witvrouw M., Arranz M.E., Pannecouque C., Declercq R., Jonckheere H., Schmit J.-C., Vandamme A.-M., Diaz J.A., Ingate S.T., Desmyter J., Esnouf R., Van Meervelt L., Vega S., Balzarini J., De Clercq E. 1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors (NNRTIs) with anti-HIV-1 activity. Antimicrob. Agents Chemother. 42:1998;618-623.
142. Wong J.K., Hezareh M., Günthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291-1295.
143. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S., Pettibone D.J., O'Brien J.A., Ball R.G., Balani S.K., Lin J.H., Chen I.-W., Schleif W.A., Sardana V.V., Long W.J., Byrnes V.W., Emini E.A. L-743,726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;2602-2605.
144. Yuasa S., Sadakata Y., Takashima H., Sekiya K., Inouye N., Ubasawa M., Baba M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44:1993;895-900.
145. Zembower D.E., Liao S., Flavin M.T., Xu Z.-Q., Stup T.L., Buckheit R.W. Jr., Khilevich A., Mar A.A., Sheinkman A.K. Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C). J. Med. Chem. 40:1997;1005-1017.
146. Zhang H., Vrang L., Backbro K., Lind P., Sahlberg C., Unge T., Öberg B. Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Res. 28:1995;331-342.